Literature DB >> 12960546

Sevoflurane confers additional cardioprotection after ischemic late preconditioning in rabbits.

Jost Müllenheim1, Dirk Ebel, Mirco Bauer, Florian Otto, André Heinen, Jan Frässdorf, Benedikt Preckel, Wolfgang Schlack.   

Abstract

BACKGROUND: Sevoflurane exerts cardioprotective effects that mimic the early ischemic preconditioning phenomenon (EPC) by activating adenosine triphosphate-sensitive potassium (KATP) channels. Ischemic late preconditioning (LPC) is an important cardioprotective mechanism in patients with coronary artery disease. The authors investigated whether the combination of LPC and sevoflurane-induced preconditioning results in enhanced cardioprotection and whether opening of KATP channels plays a role in this new setting.
METHODS: Seventy-three rabbits were instrumented with a coronary artery occluder. After recovery for 10 days, they were subjected to 30 min of coronary artery occlusion and 120 min of reperfusion (I/R). Controls (n = 14) were not preconditioned. LPC was induced in conscious animals by a 5-min period of coronary artery occlusion 24 h before I/R (LPC, n = 15). Additional EPC was induced by a 5-min period of myocardial ischemia 10 min before I/R (LPC+EPC, n = 9). Animals of the sevoflurane (SEVO) groups inhaled 1 minimum alveolar concentration of sevoflurane for 5 min at 10 min before I/R with (LPC+SEVO, n = 10) or without (SEVO, n = 15) additional LPC. The KATP channel blocker 5-hydroxydecanoate (5-HD, 5 mg/kg) was given intravenously 10 min before sevoflurane administration (LPC+SEVO+5-HD, n = 10).
RESULTS: Infarct size of the area at risk (triphenyltetrazolium staining) was reduced from 45 +/- 16% (mean+/-SD, control) to 27 +/- 11% by LPC (P < 0.001) and to 27 +/- 17% by sevoflurane (P = 0.001). Additional sevoflurane administration after LPC led to a further infarct size reduction to 14 +/- 8% (LPC+SEVO, P = 0.003 vs. LPC; P = 0.032 vs. SEVO), similar to the combination of LPC and EPC (12 +/- 8%; P = 0.55 vs. LPC+SEVO). Cardioprotection induced by LPC+SEVO was abolished by 5-HD (LPC+SEVO+5-HD, 41 +/- 19%, P = 0.001 vs. LPC+SEVO).
CONCLUSIONS: Sevoflurane administration confers additional cardioprotection after LPC by opening of KATP channels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960546     DOI: 10.1097/00000542-200309000-00017

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  6 in total

1.  Delayed neuroprotection induced by sevoflurane via opening mitochondrial ATP-sensitive potassium channels and p38 MAPK phosphorylation.

Authors:  Zhi Ye; Qulian Guo; Na Wang; Pingping Xia; Yajing Yuan; E Wang
Journal:  Neurol Sci       Date:  2011-07-01       Impact factor: 3.307

2.  Mechanisms of xenon- and isoflurane-induced preconditioning - a potential link to the cytoskeleton via the MAPKAPK-2/HSP27 pathway.

Authors:  Nina C Weber; Octavian Toma; Jessica I Wolter; Nicole M Wirthle; Wolfgang Schlack; Benedikt Preckel
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

3.  Volatile anaesthetics and cardiac protection in abdominal surgery.

Authors:  Jasminka Kopić
Journal:  Wien Klin Wochenschr       Date:  2015-07-10       Impact factor: 1.704

4.  The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC-epsilon and p38 MAPK.

Authors:  Nina C Weber; Octavian Toma; Jessica I Wolter; Detlef Obal; Jost Müllenheim; Benedikt Preckel; Wolfgang Schlack
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

5.  Downregulation of Na+/Ca2+ Exchanger Isoform 1 Protects Isolated Hearts by Sevoflurane Postconditioning but Not by Delayed Remote Ischemic Preconditioning in Rats.

Authors:  Yang Yu; Cheng-Hui Zhou; Yun-Tai Yao; Li-Huan Li
Journal:  Chin Med J (Engl)       Date:  2017-09-20       Impact factor: 2.628

Review 6.  Gaseous mediators: an updated review on the effects of helium beyond blowing up balloons.

Authors:  Nina C Weber; Benedikt Preckel
Journal:  Intensive Care Med Exp       Date:  2019-12-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.